What is the potential role and limitations of botulinum toxin in TMD therapy?

What is the potential role and limitations of botulinum toxin in TMD therapy?

• A. BTX cures TMD by restoring joint anatomy
• B. BTX can reduce muscle hyperactivity and pain in refractory myofascial TMD; evidence is limited, benefits temporary, and risks include weakness and dysphagia
• C. BTX is the first-line therapy for all TMD
• D. BTX is contraindicated in all TMD cases

Answer: (C)

Botulinum toxin in TMD therapy is used as an adjunct for muscle-driven pain, not as a cure or joint-restoring treatment. It can help when myofascial TMD persists despite conservative care by reducing excessive muscle activity, which often lowers pain and muscle soreness. However, the benefits are limited in scope and temporary in duration, typically lasting a few months, so repeated injections may be needed over time. Risks include weakness of the injected muscles and transient difficulty swallowing (dysphagia), with dose- and spread-related concerns. Because it does not fix joint structure and its effect wears off, it is not a first-line therapy for all TMD patients. It is also not contraindicated in every case; it’s considered in selective, refractory situations as part of a multimodal treatment plan. Injection sites commonly include affected jaw muscles, such as the masseter or temporalis, and patient selection, technique, and overall management are key to good outcomes.

Botulinum toxin in TMD therapy is used as an adjunct for muscle-driven pain, not as a cure or joint-restoring treatment. It can help when myofascial TMD persists despite conservative care by reducing excessive muscle activity, which often lowers pain and muscle soreness. However, the benefits are limited in scope and temporary in duration, typically lasting a few months, so repeated injections may be needed over time. Risks include weakness of the injected muscles and transient difficulty swallowing (dysphagia), with dose- and spread-related concerns. Because it does not fix joint structure and its effect wears off, it is not a first-line therapy for all TMD patients. It is also not contraindicated in every case; it’s considered in selective, refractory situations as part of a multimodal treatment plan. Injection sites commonly include affected jaw muscles, such as the masseter or temporalis, and patient selection, technique, and overall management are key to good outcomes.